Recursion Pharmaceuticals stock has struggled over the long haul, with a steep five year share price decline set against valuation checks that still do not mark it out as a clear bargain today.

• Over the past five years, Recursion Pharmaceuticals has fallen about 87.9%, which puts the current US$3.17 share price in the context of a long period of weak returns for shareholders.
• Recent collaboration progress with Genentech can support confidence in Recursion Pharmaceuticals' drug discovery platform. At the same time, ongoing clinical development and funding needs may continue to weigh on how investors think about risk and required returns.
• Recursion Pharmaceuticals passes only 2 of 6 valuation checks, which leans more expensive than cheap on the broader metrics.

The issue now is whether Recursion Pharmaceuticals' current valuation leaves enough potential upside to compensate investors for the risks in the story.

Does Recursion Pharmaceuticals Look Pricey on Sales?

P/S is often a clean way to compare early stage biotechs like Recursion Pharmaceuticals, since many are still reporting losses.

Recursion Pharmaceuticals currently trades on a P/S ratio of about 30.7x. That is well above the broader biotech industry average of around 11.0x and also above the stated peer average of roughly 11.1x. So you are paying a much higher price for each dollar of current revenue than for a typical biotech stock.

The valuation model that blends factors such as growth, margins, size and risk implies a fair P/S ratio close to 0.0x. The figure itself is not a precise target. Instead it signals that the framework is heavily penalising ongoing losses and risk, and that Recursion Pharmaceuticals screens as very expensive on this measure. Despite progress in the Genentech collaboration, the current P/S multiple still sits at a substantial premium to sector norms.

On the P/S multiple, Recursion Pharmaceuticals stock appears overvalued and requires investors to pay a steep premium for its current revenue base.

The Recursion Pharmaceuticals Narrative: What Would Justify Today's Price?

For Recursion Pharmaceuticals, Simply Wall St Narratives pick up where the valuation puzzle leaves off by spelling out what would need to happen to revenue growth, margins and earnings for the stock to be worth materially more or less than it is today, based on scenarios shared on the Community page. Each Narrative ties a single fair value estimate to a clear set of potential catalysts and risks so you can track which storyline is getting closer to reality over time.

Community views on Recursion Pharmaceuticals sit at opposite extremes, with some seeing a transformed TechBio platform and others focusing on insider behaviour and past share price damage.

Bull case: 62% undervalued

"With validated clinical data, significant milestone payments from partners like Roche, and a cash runway extending through 2027, Recursion is transitioning into a commercial-stage TechBio leader..."

Bear case: 61% overvalued

"All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling..."

Do you think there's more to the story for Recursion Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Recursion Pharmaceuticals screens as overvalued on market multiples, with its P/S ratio sitting well above sector peers and broader checks pointing to a weak value profile. The extreme gap between the current multiple and what the framework flags as reasonable reflects how heavily losses and execution risk are being priced in. The central question for investors is whether Recursion Pharmaceuticals can turn its platform and partnerships into durable revenue and margin progress that eventually makes today’s premium look justified, or whether the market is already paying too much for a still speculative story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.